JPH0459736A - Oral composition - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an oral composition containing anti-caries antibodies and anti-periodontal disease antibodies, and more specifically, oral compositions containing these antibodies in a stable manner. relating to things.

[Problems to be solved by conventional techniques and inventions] Conventionally,
It is known that caries and periodontal disease can be prevented by incorporating caries-preventive antibodies and periodontal disease-preventive antibodies into oral compositions (JP-A-60-28937, JP-A-60-38327, 60-
No. 38329, No. 60-146834, No. 61-1120
28, 61112029, 61-112030).

However, in oral compositions, alkyl sulfates such as sodium lauryl sulfate are usually incorporated as anionic activators in order to improve foaming properties, thereby improving the dispersibility of active ingredients and improving the feeling of use. However, the above-mentioned antibodies have a problem in that the alkyl sulfate causes protein denaturation, resulting in a decrease in titer.

Therefore, as a method for stabilizing antibodies in oral compositions containing alkyl sulfates, it has been proposed to use nonionic active agents or gelatin-like substances in combination with alkyl sulfates (JP-A-59-232352). Public bulletin, 61-112
However, the stabilization of the antibody is still insufficient.

In this case, this problem can be solved if an anionic activator is not included, but if an anionic activator is not included, the foaming properties will decrease, making it difficult to distribute the active ingredient to every corner of the oral cavity, and the use of This can lead to the problem of poor feeling.

Therefore, there is a need for the development of techniques to further stabilize antibodies in the presence of anionic activators.

[Means and effects for solving the problem] The present inventors conducted various studies in order to meet the above-mentioned needs, and found that when glycerin organic acid fatty acid ester salt is used as an anion activator, caries prevention antibodies, periodontal It has been found that protein denaturation of disease-preventing antibodies is prevented as much as possible, that these antibodies are stably incorporated into oral compositions, and that the effects of the antibodies are effectively exhibited even after long-term storage.

Furthermore, the present inventors have found that when a nonionic activator is used in combination with the glycerol organic acid fatty acid ester salt, the stabilization of the above-mentioned antibody can be further enhanced, and the present invention has been completed.

The present invention will be explained in more detail below.

The oral composition according to the present invention contains a caries preventive antibody and/or a periodontal disease preventive antibody, and uses glycerin organic acid fatty acid nitrile salt as an anion activator.

Here, the caries-preventing antibodies and periodontal disease-preventing antibodies include caries-causing bacteria such as Streptococcus mutans, Bacteroides gingivalis, Actinohacillus actinomycetemcomitans, Actinomyces viscosus, and periodontal disease. Antibodies are obtained by immunizing mammals with causative bacteria or their bacterial cell components, and these antibodies can be prepared using known methods, such as JP-A No. 60-28937,
No. 60-38327, No. 60-38329, 60146
The methods described in Publications No. 834, No. 61-112028, No. 61112029, and No. 61-112030 can be adopted, and the antibodies described in these publications can be used.

Note that, as described in these publications, the antibody may be blended as an antiserum or milk containing the antibody, or an antibody separated from these antiserum or milk may be blended.

Moreover, one type of antibody may be used alone or two or more types may be used in combination. Furthermore, the dosage and compounding amount of the antibody can also be the amounts described in the above-mentioned publication.

As the glycerin organic acid fatty acid ester salt, organic acids such as succinic acid, citric acid, tartaric acid, diacetyltartaric acid, etc., and fatty acids having 8 to 18 carbon atoms are preferably used.

In addition, as salts, alkali metals, alkaline earth metals,
Alkanolamines and salts of basic amino acids are preferred.

In this case, a salt that partially or completely neutralizes glycerin fatty acid ester and has a 1% aqueous solution with a pH of 4 to 10 is preferably used.

Specifically, as the glycerin organic acid fatty acid ester salt, glycerin succinic acid lauric acid ester, glycerin succinic acid capric acid ester, glycerin succinic acid myristate ester, glycerin citric acid lauric acid ester, glycerin tartrate acid lauric acid ester, glycerin succinic acid ester Examples include sodium salts, potassium salts, magnesium salts, lysine salts, etc. of palmitic acid ester, glycerin succinic acid coconut oil fatty acid ester, glycerin citric acid myristate ester, glycerin diacetyl tartrate lauric acid ester, and these salts can be used alone or in combination. The above can be used in combination. The blending amount is not particularly limited, but it is preferably 0.2 to 3% (by weight).

It is preferable to further include a nonionic active agent in the oral composition of the present invention, and by using the nonionic active agent in combination with the glycerin organic acid fatty acid ester salt, the antibody can be further stabilized.

Examples of nonionic activators include sucrose fatty acid ester, polyglycerin fatty acid ester, fatty acid jetanolamide, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, etc.
One or more of these can be blended.

In this case, it is preferable that the amount of the nonionic activator is 0.5 to 5 times the weight of the glycerin organic acid fatty acid ester salt in terms of antibody stability, usability, and taste.

The oral composition of the present invention can be prepared as a toothpaste, a mouthwash, etc.
However, appropriate components can be blended depending on the type and the like. For example, in the preparation of toothpaste, abrasives, binders, thickeners, sweeteners, fragrances, preservatives, etc. can be added, and various active ingredients can also be added in addition to the above-mentioned antibodies.

C Effects of the Invention] The oral composition of the present invention uses a glycerin organic acid fatty acid ester salt as an anion activator, so that caries prevention antibodies and periodontal disease prevention antibodies are stably blended over a long period of time.
These antibodies effectively exhibit their effects even after long-term storage. In addition, it has good foamability and taste, and has an excellent feeling of use.

Next, the effects of the present invention will be specifically explained using experimental examples.

[Experiment example]

A toothpaste having the following composition was prepared using antibody (1) obtained by immunizing a horse with Streptococcus mutans and antibody (2) obtained by immunizing a horse with Bacteroides gingivalis as antibodies.

This was filled into a tube and stored in a 40° C. thermostat for one month, after which the residual titer of the antibody was measured by the following method. The results are shown in Tables 1 and 2.

Note that antibody I was prepared according to the method described in Example 3 of JP-A-60-28937, and antibody Ⅰ was prepared according to the method described in JP-A-60-28937, Example 3.
The experiment was carried out according to the method described in the experimental example of Japanese Patent No. 0-142'915.

Atsushi 1" 1 [Acquisition Aluminum hydroxide 40% by weight 60% Sorbitol 35 Propylene glycol 3 Carboxymethylcellulose 1.0 Sodium carrageenan Gelatin Saccharin Flavor Sodium monofluorophosphate 0.5 0.5 0.1 1, O 0,73 Preservative Agent (methyl paraoxybenzoate) Anionic activator shown in the table Nonionic activator antibody I or ■ Oo 1 .

O8 100,0 Measurement of titer Method: Add 4.0g of toothpaste to PBS-Tween (20) (
The suspension was dispersed in phosphate physiological buffer (pH 7.4), centrifuged at 17,000 rpm for 20 minutes, the supernatant was collected, and the antibody titer was measured by ELISA.

Antibody residual titer = B/AX100 A: Initial antibody titer B: 40'C, Antibody titer after 1 month storage Table Antibody■ Antibody■ (Caries prevention antibody) (Periodontal disease prevention antibody) ( Note) Monogly: Sodium urinated with glycerin sulfur SDS Sodium nilauryl sulfate Based on the results in Tables 1 and 2, when glycerin organic fatty ester salt is used as an anion activator, it is compared with when sodium lauryl sulfate is used. It was found that the antibody titer could be kept stable by using a nonionic activator, and it was found that the antibody could be more stably formulated by using a nonionic active agent in combination.

Examples will be shown below, but the present invention is not limited to the following examples.

[Example 1] Toothpaste dicalcium phosphate 45% carboxymethyl cellulose 1 Sodium carrageenan 0.5 Sorbit 35 Propylene glycol 3 Gelatin 1.0 Sodium monofluorophosphate Antibody I Sodium methylsaccharin paraoxybenzoate Flavored purified water [Example 2 [Example 3] Toothpaste aluminum hydroxide carrageenan sorbitol propylene glycol peptide sodium monofluorophosphate antibody ■ Butyl saccharin sodium paraoxybenzoate 100, ○ 40% by weight 0.5 Flavor purified water [Example 3] Toothpaste anhydrous sorbitol silicate polyethylene glycol 1, ○ Remaining 100, 0 20% by weight Casein antibody I Sodium ethylsaccharin paraoxybenzoate Flavor Purified water [Example 4] Toothpaste Aluminum hydroxide 100, 0 40% by weight Sodium alginate and droxyethyl cellulose sorbitol propylene glycol 0, 3 1 , 0 Sucrose palmitate ester peptide Sodium monofluorophosphate antibody ■ Methyl paraoxybenzoate Stevioside Flavor Purified water [Example 5] Toothpaste Hydroxyethyl silicic acid Cellulose xanthan gum Sorbitol Polyethylene glycol 100, 0 20% by weight 0, 5 0, 5 Decaglycerine monolaurate gelatin dextranase aF Antibody I Methylsaccharin sodium paraoxybenzoate Flavored ice making [Example 6] Toothpaste silicic anhydride sorbitol polyethylene glycol zoo.

20% by weight POE cured hiscin 0 mol) Collagen aF Antibody ■ Sodium paraoxybenzoate methylsaccharin fragrance Purified water [Example 7] Detergent Sorbitol alcohol Sodium alanine monofluorophosphate Antibody I Sodium methylsaccharin paraoxybenzoate 100° 10% by weight Perfume purified water [Example 8] Mouthwash sorbitol alcohol -lucucrose stearate ester peptide dextranase aF antibody■ Methyl paraoxybenzoate stevioside fragrance [Example 9] Mouthwash sorbitol 0.5 Remaining 100, 0 10 Weight% 100, 0 10% by weight Glycerin Succinate Myristine Strictly Decaglycerin Monostearate Casein Alanine a F Antibody I Paraoxybenzoate Methyl Aspartame Flavor Purified Water 100° [Example 10] Mouthwash Sorbitol Alcohol P OE (20) Sorbitan Monooleate collagen nF2 antibody ■ Methyl paraoxybenzoate 10% by weight Sodium saccharin Ol Flavor ○.

Claims (1)

[Claims] 1. An oral composition containing a caries-preventing antibody and/or a periodontal disease-preventing antibody, which contains a glycerin organic acid fatty acid ester salt.